Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NUC-2020
- Development stage
- Preclinical
- Lead developer
- Nucorion Pharmaceuticals
- Modality
- Small Molecules
01
Overview
NUC-2020 is an investigational liver-targeted therapeutic being developed by Nucorion Pharmaceuticals for the treatment of hepatocellular carcinoma (HCC). The candidate utilizes Nucorion's proprietary Liver Targeting Platform (LTP) technology, which is engineered to direct active therapeutic agents specifically to the liver, thereby increasing local concentration and efficacy while reducing systemic side effects. NUC-2020 is currently in the lead optimization phase of preclinical development. While its specific molecular target remains undisclosed, the program focuses on addressing the high unmet need in primary liver cancer through precision delivery technology.
Beyond the preview
Go deeper on NUC-2020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NUC-2020.